patent/CN-102112130-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102112130-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
filingDate	2009-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b75a36f04cf0c2e88f80109194d9aa23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b4017cb14a37d64732d1c35e7393348 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f208ed7dada24b197557013ced0618c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9096378b778b003dc27612a967c1549c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05a867d262b00eb9cd86075a1c775887
publicationDate	2011-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-102112130-A
titleOfInvention	Pyrazine derivatives as epithelial sodium channel blockers
abstract	A compound of Formula I or a hydrate or solvate thereof, where R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, R<8>, R<9> and R<10> have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104302648-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104302648-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112225695-A
priorityDate	2008-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467076128

Total number of triples: 34.